MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Bristol-Myers Squibb Co.

Open

SectorGezondheidszorg

47.61 -1.71

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

46.95

Max

48.84

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.1B

76M

Verkoop

442M

12B

K/W

Sectorgemiddelde

14.05

57.333

EPS

1.67

Dividendrendement

5.04

Winstmarge

0.616

Werknemers

34,100

EBITDA

-1.9B

2.6B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+18.22% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

5.04%

2.63%

Volgende dividenddatum

1 mei 2025

Volgende Ex Dividend datum

4 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-21B

100B

Vorige openingsprijs

49.32

Vorige sluitingsprijs

47.61

Technische score

By Trading Central

Vertrouwen

Neutral Evidence

Bristol-Myers Squibb Co. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 apr 2025, 11:32 UTC

Winsten

Bristol Myers Squibb Swings to Profit in 1Q, Increases Fiscal Year Guidance

11 mrt 2025, 10:13 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

11 mrt 2025, 10:13 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

2seventy Bio Shares Soar Premarket on Deal to be Acquired by Bristol Myers

24 apr 2025, 21:24 UTC

Top Nieuws
Winsten

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 14:15 UTC

Top Nieuws
Winsten

Bristol Myers Squibb Shares Sink Despite Better-than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 apr 2025, 12:37 UTC

Marktinformatie
Winsten

Bristol Myers Squibb Raises Guidance, But Any Pharma-Sector Tariffs Could be a Drag -- Market Talk

24 apr 2025, 11:17 UTC

Winsten

Bristol Myers Squibb Swings to Profit in 1Q, Increases FY Guidance

24 apr 2025, 11:13 UTC

Top Nieuws
Winsten

Bristol Myers Squibb Posts Better-than-Expected Earnings, Raises Full-Year Guidance -- Barrons.com

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Raised 1Q Rev Outlook Reflecting Strong Performance of Growth Portfolio, Better-Than-Expected 1Q Legacy Portfolio Sales and Favorable Impact of About $500M Related to Forex Rates >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb Latest 1Q Includes Acquired IPRD Charge of $188M >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q U.S. Revenue Fell 7% to $7.87B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Guidance Revisions Include Estimated Impact of Current Tariffs on U.S. Products Shipped to China, but Do Not Account for Any Potential Pharmaceutical Sector Tariffs >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Growth Portfolio Revenue Rose 16% to $5.56B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Opdivo, Breyanzi, Reblozyl and Camzyos and Reflects Strong Early U.S. Launch of Cobenfy >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Adjusted Gross Margin 73.1% >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q International Revenue Fell 2% to $3.33B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Continued Generic Impact on Revlimid, Pomalyst, Sprycel and Abraxane, as Well as Impact From U.S. Medicare Part D Redesign >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Legacy Portfolio Rev Fell 20% to $5.64B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Adj EPS $1.80 >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb Raises 2025 View To Rev $45.8B-$46.8B Vs Prior View $45.5B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Gross Margin 72.9% >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb Raises 2025 View To Adj EPS $6.70-Adj EPS $7.00 Vs Prior View $6.55-$6.85 >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q Rev $11.2B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol Myers Squibb 1Q EPS $1.20 >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol-Myers Squibb 1Q Adj EPS $1.80 >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol-Myers Squibb 1Q Rev $11.2B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol-Myers Squibb 1Q Net $2.46B >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol-Myers Squibb Sees FY Adj EPS $6.70-Adj EPS $7.00 >BMY

24 apr 2025, 10:59 UTC

Winsten

Bristol-Myers Squibb 1Q EPS $1.20 >BMY

14 mrt 2025, 09:30 UTC

Top Nieuws

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

Peer Vergelijking

Prijswijziging

Bristol-Myers Squibb Co. Prognose

Koersdoel

By TipRanks

18.22% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 57.56 USD  18.22%

Hoogste 70 USD

Laagste 36 USD

Gebaseerd op 19 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bristol-Myers Squibb Co. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

19 ratings

5

Buy

13

Hold

1

Sell

Technische score

By Trading Central

47.54 / 48.82Steun & Weerstand

Korte Termijn

Neutral Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.